The Cooper Companies, Inc. (NASDAQ:COO) is Parkman Healthcare Partners LLC's 6th Largest Position

Parkman Healthcare Partners LLC decreased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 6.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 274,569 shares of the medical device company's stock after selling 18,024 shares during the period. Cooper Companies makes up approximately 3.4% of Parkman Healthcare Partners LLC's holdings, making the stock its 6th largest holding. Parkman Healthcare Partners LLC owned approximately 0.14% of Cooper Companies worth $25,241,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its holdings in shares of Cooper Companies by 517.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,529,477 shares of the medical device company's stock worth $324,466,000 after buying an additional 2,957,421 shares during the period. Norges Bank purchased a new position in shares of Cooper Companies in the fourth quarter worth about $217,906,000. FMR LLC increased its holdings in shares of Cooper Companies by 97.6% in the fourth quarter. FMR LLC now owns 2,218,112 shares of the medical device company's stock worth $203,911,000 after buying an additional 1,095,805 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Cooper Companies in the fourth quarter worth about $64,826,000. Finally, Victory Capital Management Inc. grew its stake in shares of Cooper Companies by 14.6% in the fourth quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company's stock worth $415,985,000 after purchasing an additional 574,899 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on COO shares. Robert W. Baird cut their target price on Cooper Companies from $117.00 to $107.00 and set an "outperform" rating on the stock in a research note on Friday, March 7th. JPMorgan Chase & Co. cut their target price on Cooper Companies from $120.00 to $110.00 and set an "overweight" rating on the stock in a research note on Friday, March 7th. Stifel Nicolaus cut their target price on Cooper Companies from $115.00 to $105.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Piper Sandler reissued an "overweight" rating and issued a $115.00 target price (down from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Finally, BNP Paribas raised Cooper Companies to a "hold" rating in a research note on Thursday, March 13th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Cooper Companies presently has an average rating of "Moderate Buy" and an average target price of $110.25.

Cooper Companies Stock Up 1.8%

Shares of COO stock traded up $1.47 during trading hours on Friday, hitting $82.92. 1,519,674 shares of the company's stock traded hands, compared to its average volume of 1,471,543. The stock's fifty day simple moving average is $80.19 and its two-hundred day simple moving average is $90.10. The Cooper Companies, Inc. has a 12-month low of $69.81 and a 12-month high of $112.38. The stock has a market cap of $16.58 billion, a price-to-earnings ratio of 42.52, a PEG ratio of 2.25 and a beta of 1.08. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The firm had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. On average, analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.